Integrity Applications, Inc. (OTCQB:IGAP), developer of the GlucoTrack®
model DF-F non-invasive blood glucose measurement device, acknowledged
World Diabetes Day 2013 today by spotlighting the potential of its
device for painless blood glucose testing.
“With its patented combination of ultrasonic, electromagnetic and
thermal technologies, GlucoTrack provides clinically acceptable accuracy
in blood glucose measurement,” said Avner Gal, President and CEO of
Integrity Applications. “I believe the device holds great potential to
address the concerns of the millions of people with diabetes worldwide
who must monitor their blood glucose level on a daily basis.”
GlucoTrack features a small sensor that clips to the earlobe and
measures the wearer’s blood glucose level by taking measurements using
three technologies. The measurements are analyzed using a proprietary
algorithm and displayed on, and verbally announced by, a small handheld
device. The company has obtained a CE Mark for its GlucoTrack Model DF-F
in Europe and intends to seek Food and Drug Administration approval for
GlucoTrack in the United States.
To watch a video detailing the benefits of GlucoTrack, please visit the
following link: http://www.youtube.com/watch?v=i9wtj179mq4
Led by the International Diabetes Federation and its member
associations, World Diabetes Day is held on November 14 and is intended
to engage millions of people worldwide in diabetes advocacy and
awareness.
About Integrity Applications, Inc.
Integrity Applications, Inc. is a medical device company focused on the
design, development and commercialization of non-invasive glucose
monitoring devices for use by people with diabetes. Integrity
Applications has developed the GlucoTrack model DF-F non-invasive
glucose monitoring device, which is designed to help people with
diabetes obtain blood glucose level measurements without the pain,
inconvenience, incremental cost, and difficulty of conventional
(invasive) spot finger stick devices. Integrity Applications works
primarily through its wholly-owned Israeli subsidiary, A.D. Integrity
Applications, Ltd. For more information please visit www.integrity-app.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Statements
contained in this news release that are not statements of historical
fact may be deemed to be forward-looking statements. Without limiting
the generality of the foregoing, words such as "intends," and "believe,"
are intended to identify forward-looking statements. Readers are
cautioned that certain important factors may affect Integrity
Applications’ actual results and could cause such results to differ
materially from any forward-looking statements that may be made in this
news release. Factors that may affect Integrity Applications’ results
include, but are not limited to, the ability of Integrity applications
to successfully commercialize the GlucoTrack DF-F; the ability of the
GlucoTrack DF-F to achieve acceptable pricing, adequate third party
reimbursement or market acceptance; the ability of Integrity
Applications to manage its growth and the expansion of its operations to
include commercialization activities; risks relating to the use of third
party manufacturers; risks relating to the development of Integrity
Applications’ sales, marketing and distribution capability, either on
its own or through collaborations with marketing partners; and the
additional risk factors described in Integrity Applications’ filings
with the U.S. Securities and Exchange Commission, including its Annual
Report on Form 10-K for the year ended December 31, 2012.
Copyright Business Wire 2013